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Abstract
Background: Hepatitis C chronic liver disease is a major cause of liver transplant in developed countries. This article
reports the first nationwide population-based survey conducted to estimate the seroprevalence of HCV antibodies
and associated risk factors in the urban population of Brazil.
Methods: The cross sectional study was conducted in all Brazilian macro-regions from 2005 to 2009, as a stratified
multistage cluster sample of 19,503 inhabitants aged between 10 and 69 years, representing individuals living in all
26 State capitals and the Federal District. Hepatitis C antibodies were detected by a third-generation enzyme
immunoassay. Seropositive individuals were retested by Polymerase Chain Reaction and genotyped. Adjusted
prevalence was estimated by macro-regions. Potential risk factors associated with HCV infection were assessed by
calculating the crude and adjusted odds ratios, 95% confidence intervals (95% CI) and p values. Population
attributable risk was estimated for multiple factors using a case–control approach.
Results: The overall weighted prevalence of hepatitis C antibodies was 1.38% (95% CI: 1.12%–1.64%). Prevalence of
infection increased in older groups but was similar for both sexes. The multivariate model showed the following to
be predictors of HCV infection: age, injected drug use (OR = 6.65), sniffed drug use (OR = 2.59), hospitalization
(OR = 1.90), groups socially deprived by the lack of sewage disposal (OR = 2.53), and injection with glass syringe
(OR = 1.52, with a borderline p value). The genotypes 1 (subtypes 1a, 1b), 2b and 3a were identified. The estimated
population attributable risk for the ensemble of risk factors was 40%. Approximately 1.3 million individuals would be
expected to be anti-HCV-positive in the country.
Conclusions: The large estimated absolute numbers of infected individuals reveals the burden of the disease in the
near future, giving rise to costs for the health care system and society at large. The known risk factors explain less
than 50% of the infected cases, limiting the prevention strategies. Our findings regarding risk behaviors associated
with HCV infection showed that there is still room for improving strategies for reducing transmission among drug
users and nosocomial infection, as well as a need for specific prevention and control strategies targeting individuals
living in poverty.
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Background
Around the world, infection by the Hepatitis C virus
(HCV) causes acute and chronic liver disease and may
lead to cirrhosis, liver failure and/or hepatocellular carcin-
oma. HCV chronic liver disease is one of the main causes
of liver transplantation in developed countries [1]. The
global prevalence of HCV infection is estimated to be
2.2%, with 170 million individuals infected (2004) [2].
The sequential population-based studies conducted in
the USA are among the few nationwide surveys to estimate
the prevalence of HCV [3-6]. In the USA, a 1.6% nation-
wide prevalence of anti-HCV was found by the National
Health and Nutrition Examination Survey Continuous
(NHANES Continuous) between 1999 and 2002 [5]. These
surveys showed a decline in the prevalence of hepatitis C
from NHANES III (1988–1994) to NHANES Continuous
(2003–2006), but this figure remained stable between
the NHANES 1999–2002 and NHANES 2003–2006 [6].
The incidence of acute hepatitis C tended to decline
over the twenty-five years of surveillance (1982–2006)
in selected counties in the USA, with intravenous drug
use (IDU) continuing to be the predominant risk factor [7].
In France, a population-based survey showed an overall
prevalence of anti-HCV of 0.84% in 2004. IDU, nasal drug
use, blood transfusion prior to 1992, having a tattoo, being
older than 29 years, social deprivation, and being born on a
continent with endemic levels higher than 2.5% were the
risk factors associated with HCV infection [8].
In Latin America, estimates of HCV prevalence range
from 1.0 to 2.3% using projections of HCV for modeling
[9]. Data from the World Health Organization (WHO)
placed Brazil among the countries with a prevalence of
hepatitis C infection ranging from 2.5% to 10% [2]. Com-
pulsory notification of acute and/or chronic hepatitis C was
implemented by the Brazilian surveillance system in 1996.
The detection rates for anti-HCV remained stable at ap-
proximately 10 cases per 100,000 individuals from 2004 to
2009, with the bulk of cases being reported in the southeast
region [10]. In Brazil, the few population-based studies
[11-13] and the vast majority of studies reporting risk fac-
tors associated with HCV infection were obtained from
selected populations in restricted areas [14-18]. In a large
sample of chronic HCV patients from different laboratories
located in all Brazilian macro-regions, genotype 1 was found
to predominate, followed by genotypes 3, 2, 4 and 5 [19].
A national seroepidemiological survey of Hepatitis A, B
and C infection was launched by the Brazilian Ministry of
Health in 2005 and completed in 2009. The epidemiology
of hepatitis A and hepatitis B for the northeast and
central-west regions and the Federal District has already
been published [20,21]. The aim of the present study was
to estimate the seroprevalence of HCV antibodies in the
five macro-regions of Brazil and the Federal District. The
association between potential risk factors and HCV
seropositivity was assessed for the country as a whole and
the population attributable risk for multiple factors was
estimated using the case–control approach. This is the
first population-based HCV antibody survey conducted in
a representative sample of the Brazilian macro-regions
and the Federal District.
Methods
Study design and sites
The national seroepidemiological survey of hepatitis A,
B and C infection was designed as a representative sam-
ple of individuals aged 10 to 19 and 20 to 69 years in the
5 Brazilian macro-regions. Participants were residents of
all 26 State capitals and the Federal District. The field-
work was conducted from 2005 to 2009. The method-
ology has been described in a prior publication [22].
In brief, a stratified multistage cluster sampling method
based on The Brazilian Institute of Geography and Statis-
tics (IBGE) census data for the year 2000 was used to se-
lect the study population. In the first step, within each
macro-region, the sample was stratified by state capital
using a constant sampling fraction. In the second step the
primary sampling units – census tracts – were drawn with
probability proportional to population size and assuring
the inclusion of all socioeconomic groups. The primary
sampling units were subsampled successively in terms of
blocks (with probability proportional to population size),
households and eligible individuals. The final analysis
weights incorporated the selection probabilities and design
effect due to the cluster sampling to obtain representative
estimates of the target population.
Data collection and variables
All sites followed the same standard protocol. Data were
collected by interview using a structured questionnaire
during household visits. Blood samples were collected
after the interviews. Both procedures were performed by
trained health personnel.
The individual variables collected were social-
demographic characteristics, blood route-related factors,
such as dental treatment, surgery, history of blood
transfusion, hospitalization, endoscopy, use of glass syringe
not related with drug abuse, tattoos, or body piercing.
Questions related to alcohol, drug consumption, lifelong
sexual behavior and health-related jobs were restricted
to persons aged 13 years or older. At the household
level, data on income and education of the head of family
and the characteristics of the household including home
ownership, water supply, sewage and solid waste disposal
were recorded [22].
Serum tests and definitions
Blood samples were collected, transported and stored
according to standard procedures. HCV antibodies were
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detected by a third-generation (Axsym, Abbott Labora-
tories, Abbott Park, Illinois) enzyme immunoassay in
central public health laboratories. The results were con-
sidered positive when the optical density (OD) was ≥ 1.2
(20% higher than the cutoff ). Samples with OD between
1.0 and 1.19 were considered indeterminate and were
retested by anti-HCV; if the second testing yielded an
indeterminate result, the sample was considered as nega-
tive. Seropositive individuals were submitted to a new
blood sample collection to perform PCR and genotyping
tests for clinical approach.
HCV RNA detection and genotyping
HCV RNA was detected using AMPLICOR™ (Roche
Version 2.0) and extracted from 200 μL serum using the
extraction reagents included in the kit, in accordance
with the manufacturer’s instructions.
A commercially available reverse hybridization-based
line probe assay (HCV Genotype assay, LiPA™) was
employed, using Amplicor’s PCR product generation.
The genotypes were identified following the manufac-
turer’s instructions.
Sample size
The sample size was based on the expected prevalence
of seropositivity for anti-HCV according to data from
blood donors by macro-region [23]. The variance was
estimated as 20% of the prevalence value for all macro-
regions and 30% for the Federal District [22]. The sam-
ple size achieved in this study matched the number of
individuals estimated for each region and age group as
previously reported.
As in the original protocol the analysis of risk factors
for anti-HCV positivity was planned for the entire coun-
try, the number of seropositive individuals identified by
the survey was large enough to detect differences in ex-
posure corresponding to an odds ratio of 2, with a fre-
quency of exposure among those not sick of 5% or
more, a power of 80% and an alpha of 5%.
Statistical analysis
Prevalence of anti-HCV with 95% confidence intervals
(95% CI) was calculated for the country, by age group
and by the five macro-regions and the Federal District.
The estimated number of persons infected was based on
the prevalence and on the census population official data
of residents from the State Capitals by age groups for
the year 2000 [24]. Prevalence was adjusted for the de-
sign effect and, when necessary, for regional variations
in sample fractions.
The distributions of potential risk factors and their re-
spective 95% CIs were calculated for the population aged
13 to 69 years old by macro-region. Possible associations
between HCV infection and potential risk factors were
assessed by calculating the Odds Ratio (OR), (95% CI)
and p-values. ORs were adjusted for the design effect
and age, and weighted for variations in sample fractions
in the different age groups and regions. Variables that
were associated with the outcome in this age-adjusted
analysis (p < 0.10) were included in a multivariate regres-
sion model by means of the Generalized Linear and La-
tent Mixed Models (GLLAMM). The two-level analysis
(individual and household) was performed using Stata 9.2
[25]. Population attributable risk—the fraction of disease
in the total study population that is attributable to the ex-
posure— was estimated for multiple factors using case–
control data according to Bruzzi et al. [26]. Population
attributable risk was also calculated for the ensemble of
variables using an accepted procedure; it is worth noting
that this estimate is not the equivalent of adding the popu-
lation attributable risks for individual factors [26].
A ROC curve was plotted to predict viremia for the
North macro-region, and to determine the cut-off for
anti-HCV positivity using the Sample rate/cut-off rate
(S/CO) ratios from the individuals tested for HCV-RNA.
Ethical issues
Interviews and blood sample collection were conducted
after written consent forms had been signed. For minors,
the legal guardian’s consent was obtained. The project
was approved by the National Research Ethics Commit-
tee (CONEP) of the Brazilian National Health Council
and by the local Research Ethics Committees in each
capital city.
Each positive result was communicated by the medical
doctor in charge of the field research and the negative
results were sent by mail. Individuals who had a positive
result were sent to referral services in each State capital
or the Federal District for further clinical evaluation.
Results
Of 19,503 individuals aged 10 to 69 years old recruited,
2,288 were in the North region (Amazon area); 3,690 in
the North-east; 3,702 in the Central-west; 1,988 in the
Federal District; 3,661 in the South-east and 4,174 in the
South. Of the total sample, 49.0% of the participants
were aged 10–19 years old (n = 9,371) and 51.0% were
20–69 (n = 10,132). Females accounted for 54.6% of the
total participants. The overall refusal rate was 2.8%,
being below 1.5% for the North, Northeast and Central-
west macro-regions and approximately 6% in the South
and Southeast macro-regions.
In Brazil, the overall weighted prevalence of HCV anti-
bodies was 1.38% (95% CI 1.12%–1.64%) in the state
capitals of the five macro-regions and the Federal Dis-
trict taken as a whole (Table 1). Seropositivity varied
from 0.68% in the Northeast to 2.10% in the North re-
gion. In all macro-regions studied, adults (aged 20–69
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years) had a higher prevalence of HCV antibodies than
the younger age-group. The highest prevalence in adults
was in the North region (3.22%; 95% CI 2.03%–4.41%).
Prevalence peaked in those aged ≥ 60 years.
The estimated number of persons ever infected in the
Brazilian State capitals and Federal District was 430,658
(95% CI 349,714–511,289), based on the HCV preva-
lence and the size of the population. The largest infected
population was in the Southeast region (190,254; 95% CI
136,110–244,548).
For the overall data set, anti-HCV positivity was similar
between genders according to the two age strata (Figure 1).
When stratified by macro-region, anti-HCV prevalence
was similar between men and women in most of the stud-
ied settings, except in the Central-West macro-region,
where men had a statistically significant higher prevalence
of HCV infection than women (chi-square = 4.9, p < 0.03)
(Figure 1).
Of 9,671 households investigated, ten contained two
individuals testing positive for anti-HCV and one
household contained three. Thirty participants were sim-
ultaneously seropositive for anti-HCV and anti-HBc
antibodies.
Of 236 anti-HCV positive individuals, 120 (50.8%) had
their blood collected for HCV-RNA testing in all the
macro-regions and Federal District, with the exception
of the North macro-region, owing to operational con-
straints. Of those retested, 36.7% (95% IC 28.4%-45.6%)
were HCV-RNA positive. The ROC curve suggested that
the cut-off point of 0.4, which yielded the higher sensi-
tivity and specificity, was OD = 4.0. Using this parameter,
32.1% individuals would also be considered infected, that
is, HCV-RNA positive, in the North region. The com-
parison of the participants who were retested (n = 120)
versus those not retested (n = 116) in relation to vari-
ables associated with HCV infection that remained in
the multivariate model showed that both groups were
similar in terms of age group, use of injected and sniffed
drugs, use of glass syringes and hospitalization. The
main difference was in socio-economic conditions
Table 1 Prevalence of hepatitis C antibodies and estimated population ever-infected in a representative sample of
individuals living in the state capitals of Brazil, 2005–2009
Setting age-group Participants Prevalence* % (95% CI) State capitals population Estimated persons ever infected n (95% CI)
Brazil
10 – 19 9,371 0.75 (0.53 – 0.98)† 7,565,695 56,970 (39,947 – 74,068)
20 – 39 5,552 1.36 (1.02 – 1.71)† 13,828,140 188,478 (140,494 – 236,462)
40 – 59 3,719 1.55 (1.09 – 2.01)† 7,941,985 122,783 (86,250 – 159,396)
60 – 69 891 3.41 (2.03 – 4.79)† 1,916,570 65,432 (38,964 – 91,900)
North
10 – 19 1,153 0.99 (0.36 –1.63) 860,922 8,601 (3,117 – 14,093)
20 – 69 1,135 3.22 (2.02 – 4.41) 2,093,269 67,403 (42,472 – 92,334)
Northeast
10 – 19 1,840 0.38 (0.10 – 0.66) 2,054,539 7,848 (2,096 – 13,601)
20 – 69 1,850 0.97 (0.48 – 1.47) 5,358,923 52,249 (25,616 – 78,883)
Midwest
10 – 19 1,803 0.99 (0.53 – 1.47) 866,536 8,657 (4,601 – 12,712)
20 – 69 1,899 1.64 (1.14 – 2.13) 1,326,575 21,703 (15,110 – 28,296)
Federal District
10 – 19 980 0.61 (0.13 – 1.09) 387,831 2,374 (524 – 4,227)
20 – 69 1,008 1.09 (0.50 – 1.68) 1,202,183 13,116 (6,011 – 20,245)
Southeast
10 – 19 1,794 0.90 (0.49 – 1.31) 3,295,110 29,755 (16,212 – 43,298)
20 – 69 1,867 1.63 (1.07 – 2.18) 11,661,984 189,857 (124,783 – 254,814)
South
10 – 19 1,801 0.51 (0.12 – 0.89) 586,270 2,978 (715 – 5,241)
20 – 69 2,373 1.70 (1.08 – 2.32) 2,043,761 34,826 (22,175 – 47,456)
* Prevalence adjusted for random effect.
† Prevalence adjusted for random effect and weighted by regions.
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(chi-square = 8.8, p = 0.012) suggesting that those better-
off were more likely to be retested. Assuming the fre-
quency of HCV-RNA-positive individuals among the
estimated persons ever infected in the present study, it
would be expected that there were approximately
158,000 (122,000 to 196,000) patients infected with
HCV.
The genotypes and subgenotypes detected were 1 (n = 3);
1a (n = 9); 1b (n = 16); 2b (n = 2); 3a (n = 14).
Tables 2, 3, 4 show the age-adjusted odds ratio for the
association between blood-related variables, sexual be-
havior and drug use and HCV infection for all the State
capitals taken together. There was a positive association
between anti-HCV antibodies and ever having received a
blood transfusion (OR = 1.83, 95% CI 1.01–3.30), having
been hospitalized in the previous 12 months (OR = 1.87,
95% CI 1.04–3.38), or having had a tattoo (OR = 1.63,
95% CI 0.95–2.80), the latter presenting a borderline
p value (Table 2). Having a current partner with hepatitis
was positively associated with HCV antibodies and nega-
tively associated with partner history of STD (Table 3).
Ever having used injected drugs was strongly associated
with HCV antibodies (OR = 12.79, 95% CI 5.19–31.50).
A statistically significant association was also found with
ever having used sniffed drugs (OR = 3.50, 95% CI 1.87–
6.54) and previous use of a glass syringe (OR = 1.67, 95%
CI 1.09–2.56) (Table 4). As for socioeconomic variables,
sewage disposal (lack of sewage system versus public sys-
tem) was associated with HCV antibodies (OR = 1.90,
95% CI 1.06–3.40).
Figure 1 Prevalence of hepatitis C infection in a representative sample of State capitals of the five Brazilian regions by sex and
age group.
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The multivariate analysis shows that a history of injected
drug use (OR = 6.65; 95% CI 2.47–17.91) and sniffed drug
use (OR = 2.59; 95% CI 1.34–5.81) were strongly asso-
ciated to HCV infection. Other risk factors were the use of
a glass syringe (OR = 1.52; 95% CI 0.97–2.36) and ever-
hospitalization, both with a borderline p value. A proxy
measure of socioeconomic conditions (sewage disposal)
was also associated with testing positive for anti-HCV.
Age, introduced in the model as a continuous variable,
showed that there was an increase in the likelihood of be-
coming infected of 0.02% for each year of life (OR = 1.02;
95% CI 1.01–1.04 (Table 5). The proportion of cases at-
tributable to each variable in the final multivariate model
ranged from 4.2% to 10.2%, and the proportion attribut-
able to all factors together was 39.9%.
Discussion
This first Brazilian nationwide hepatitis survey showed
1.38% HCV positivity in a representative sample of
19,503 adolescents and adults in all macro-regions. Ap-
proximately 1.3 million individuals would be expected to
be anti-HCV-positive in the country under the assump-
tion of similar anti-HCV antibody prevalence for the
Brazilian population as a whole (population of 169.8 mil-
lion, as of 2000). The current population-based survey
detected a lower prevalence of anti-HCV antibody than
that previously reported by the WHO for the country
[2], shifting from intermediate to low prevalence.
The few nationwide population-based studies have
reported prevalence of anti-HCV antibodies of 1.3% in
the USA [6] and 1.0% in France [27], which are similar
Table 2 Age-adjusted odds ratio of hepatitis C infection for blood route-related factors in the urban Brazilian
population
Risk factors Participants HCV infection n (%) ORadjusted (CI)* p-value
Dental treatment
Never 2,034 22 (1.1) 1.0 -
Past 12 months 8,655 99 (1.1) 0.77 (0.41 – 1.47) 0.436
Ever 8,772 114 (1.3) 0.91 (0.47 – 1.77) 0.795
Surgery
Never 11,481 108 (0.9) 1.0 -
Past 12 months 1,689 31 (1.8) 1.38 (0.72 – 2.64) 0.327
Ever 6,270 96 (1.5) 0.93 (0.60 – 1.42) 0.730
Blood transfusion
Never 18,122 196 (1.1) 1.0 -
Past 12 months 256 10 (3.9) 1.45 (0.65 – 3.21) 0.365
Ever 843 24 (2.9) 1.83 (1.01 – 3.30) 0.043
Hospitalization
Never 13,095 143 (1.1) 1.0 -
Past 12 months 1,308 25 (1.9) 1.87 (1.04 – 3.38) 0.037
Ever 5,032 67 (1.3) 1.46 (0.97 – 2.19) 0.065
Endoscopy
Never 16,695 190 (1.1) 1.0 -
Past 12 months 904 13 (1.4) 1.14 (0.53 – 2.47) 0.729
Ever 1,785 29 (1.6) 1.17 (0.64 – 2.15) 0.615
Tatoo
No 18,034 202 (1.1) 1.0 -
Yes 1,459 33 (2.3) 1.63 (0.95 – 2.80) 0.076
Body piercing
No 17,859 215 (1.2) 1.0 -
Yes 1,634 20 (1.2) 0.97 (0.51 – 1.87) 0.935
Health-care related job
No 15,424 195 (1.3) 1.0 -
Yes 1,206 20 (1.7) 0.91 (0.46 – 1.80) 0.783
* Adjusted for random effect and age weighted by age groups and regions.
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to that found in this study. An increase in anti-HCV
prevalence with age was found in the large census sur-
veys conducted in the USA. Peak HCV prevalence was
found among adults aged 30-49 years in the first census
survey (1988–1994), shifting to 40–49 years in the later
surveys (1999–2002; 2003–2006; 2007–2008) [6]. Al-
though our results also showed increased HCV exposure
with age, the peak prevalence was observed in the older
age group. Increased HCV infection among the adult
population has also been reported in selected regions of
Brazil [11,13] and among first-time blood donors [28].
The highest prevalence of the HCV marker (2.1%) was
in the North macro-region of Brazil, which is below the
2.5% prevalence threshold for low endemicity according
to WHO criteria [2]. However, most of the estimated
infected individuals resided in the Southeast region
(~220,000), since approximately 14 million individuals
aged 10 to 69 years live in these highly urbanized State
capitals that include the cities of Sao Paulo and Rio de
Janeiro. The burden of infection in absolute terms thus
has an uneven geographical distribution, concentrated in
the South and Southeast macro-regions. According to
the official surveillance system, the residents of the
southeast and south had higher HCV detection rates
(above the national figures) than the residents in the
north, northeast and central-west from 2003 through
2009 (unpublished data). One likely explanation for the
higher detection rates in the south and southeast may be
better access to and organization of the health system of
these regions [29]. The surveillance data for HCV may
also underestimate the prevalence of HCV infection in
the country as a whole, in view of the prevalence found
by this population-based survey. Under-reporting of
HCV infection by other national surveillance systems
has also been discussed for Europe [30,31] and for the
USA [32], pointing to the need for updated population-
based studies for public health purposes.
Interestingly, those participating in this national survey
showed similarities in terms of the risk profile for HCV
acquisition, with slightly higher frequencies for blood
transfusion (7.8%), tattoos (12.2%) and sniffed drugs
(5.9%) in the south macro-region (data not shown). In
this household survey, injected and sniffed drug use was
strongly associated with HCV antibodies in multivariate
Table 3 Age-adjusted odds ratio of hepatitis C infection for sexual behavioral-related factors in the urban Brazilian
population
Risk factors Participants HCV infection n (%) ORadjusted (95% CI)* p-value
Initiated sexual life
No 4,137 36 (0.9) 1.0 -
Yes 12,468 179 (1.4) 0.97 (0.56 – 1.68) 0.912
Condom use
Always 3,831 37 (1.0) 1.0 -
Sometimes 1,944 29 (1.5) 1.71 (0.85 – 3.43) 0.132
Never 6,077 103 (1.7) 1.04 (0.56 – 1.96) 0.888
Current partner had hepatitis
No 10,263 140 (1.4) 1.0 -
Yes 445 13 (2.9) 2.16 (1.00 – 4.65) 0.050
Bisexual partner
No 11,417 158 (1.4) 1.0 -
Yes 276 4 (1.4) 0.83 (0.29 – 2.42) 0.737
Unknown 775 17 (2.2) 1.41 (0.69 – 2.87) 0.343
Sexual partners with STD
No 11,086 164 (1.5) 1.0 -
Yes 819 10 (1.2) 0.43 (0.20 – 0.93) 0.031
Previous STD
No 11,079 153 (1.4) 1.0 -
Yes 1,301 25 (1.9) 0.96 (0.50 – 1.83) 0.901
Another sexual partner besides current
No 4,703 64 (1.4) 1.0 -
Yes 6,978 101 (1.4) 1.10 (0.73 – 1.65) 0.657
* Adjusted for random effect and age weighted by age groups and regions.
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Table 4 Age-adjusted odds ratio of hepatitis C infection for drug use-related factors in the urban Brazilian population
Risk factors Participants HCV infection n (%) ORadjusted (95% CI)* p-value
Ever use of smoked drugs
No 14,726 177 (1.2) 1.0 -
Yes 1,839 38 (2.1) 1.47 (0.88 – 2.46) 0.141
Ever use of inhalated drugs
No 16,293 206 (1.3) 1.0 -
Yes 265 09 (3.4) 2.68 (0.85 – 8.45) 0.093
Ever use of sniffed drugs
No 15,827 189 (1.2) 1.0 -
Yes 749 25 (3.3) 3.50 (1.87 – 6.54) 0.000
Ever use of injected drugs
No 16,463 204 (1.2) 1.0 -
Yes 70 11 (15.7) 12.79 (5.19 – 31.5) 0.000
Injections with glass syringe
No 13,450 148 (1.1) 1.0 -
Yes 2,931 63 (2.2) 1.67 (1.09 – 2.56) 0.019
Alcohol consumption
None 10,237 129 (1.3) 1.0 -
Light consumption 5,376 67 (1.2) 0.75 (0.50 – 1.12) 0.155
Heavy consumption 978 16 (1.6) 0.84 (0.41 – 1.69) 0.619
Dependent 41 03 (7.3) 2.88 (0.79 – 10.49) 0.108
* Adjusted for random effect and age weighted by age groups and regions.
Table 5 Multivariate analysis of hepatitis C infection for potential risk factors and estimated population attributable
risk in the urban Brazilian population
Factors associated ORadjusted (95% CI)* p-value Population Arributable risk %
Age 1.02 (1.01 – 1.04) 0.001 -
Ever use of injected drugs
No 1.0 -
Yes 6.65 (2.47 – 17.91) < 0.0001 4.3
Ever use of sniffed drugs
No 1.0 -
Yes 2.59 (1.34 – 5.01) 0.005 7.2
Injection with glass syringe
No 1.0 -
Yes 1.52 (0.97 – 2.36) 0.065 10.2
Hospitalization
Never 1.0 -
Past 12 months 1.90 (1.03 – 3.51) 0.040 5.0
Ever 1.44 (0.94 – 2.21) 0.094 8.7
Sewage disposal
Public system 1.0 -
Septic tank 1.39 (0.91 – 2.12) 0.125 8.8
Other destination 2.53 (1.38 – 4.65) 0.003 3.9
39.9**
* Adjusted for random effect and age weighted by age groups and regions.
** Summary population attributable risk.
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analysis. These findings accord with the literature
regarding injected drug use as the main source of trans-
mission of HCV infection in developed countries and
with the reports of sniffed drugs as another important
mode of HCV acquisition in developing countries, as
previously reported in selected Brazilian populations
[33]. In the present survey, a history of previous
hospitalization and use of injections with glass syringe
not related to drug use were also associated with HCV
seropositivity, both of which have been widely reported
as epidemiological risk factors for HCV infection world-
wide [1,2]. In our survey, a socioeconomic marker of ex-
treme poverty (no sewage disposal) remained associated
with anti-HCV prevalence (OR = 2.53), after adjusting
for confounding factors. Although there is no biological
plausibility for social deprivation and increased risk of
HCV infection, the former may be a surrogate marker
for being at risk for HCV transmission. In a countrywide
survey in France, social factors remained associated with
HCV infection after adjusting for known risk factors as
in our study. Nevertheless, having ever used drugs, hav-
ing tattoos, and having being incarcerated were corre-
lated with social deprivation [8]. The USA HCV
prevalence survey also reported a correlation of infection
by drug use with low family income, high number of sex
partners, and non-injected drug use [5]. Furthermore,
studies using cross-sectional designs such as our survey
cannot sort out the temporal relationships between the
potential risk factors and the outcomes.
The estimated population attributable risk indicates that
the risk factors identified explain approximately 40% of all
cases of infection. The higher population attributable risk
percent found for “ever use of sniffed drugs” (7.2%) than
for “ever use of injected drugs” (4.3%) was probably due to
the lower frequency of IDUs than of sniffed drug users in
the studied population. Although we cannot evaluate to
what extent there was an underreporting of injection drug
use because of stigma and discrimination in our study, the
frequencies we found (data not shown) seem consonant
with the national survey conducted by the Brazilian Cen-
ter of Information on Psychotropic drugs (CEBRID) and a
study among hospitalized patients [34,35]. In relation to
IDU, as the population attributable risk is related to the
general population (injecting and non-injecting drug
users), the attributable risk among the exposed (injecting
drug users) will be greater and therefore the proportion of
infection in that group that could be prevented by elimin-
ating the exposure would be larger among IDUs.
One limitation of this survey is that it included a sam-
pling of the capital cities of the five Brazilian macro-
regions and the Federal District and was not designed as
part of a census survey [22] as was NHANES [3]. There-
fore, the low prevalence of anti-HCV detected in all
macro-regions may not reflect the levels of infection
outside the study settings, such as in rural areas, and
specific pockets. Since this investigation was planned as
a population study, specific high-risk groups for HCV
acquisition, such as institutionalized or incarcerated
individuals, were excluded. Therefore, the prevalence
reported here should be considered a conservative esti-
mate of anti-HCV prevalence.
It should be noted that, in view of the low frequency
of HCV antibodies for the country as a whole, the risk
factor analysis was performed for the entire data set and
not by macro-region. This had been anticipated by the
study protocol [22].
Another methodological issue regarding the interpret-
ation of our findings is that a sole marker of HCV infection
may lead to misclassification, owing to false positive results.
However, it would be a non-differential misclassification,
underestimating the associations reported. For this reason,
the strength of association may also be conservative [36].
We acknowledge that the approximately 40% of HCV-
RNA positivity among anti-HCV positive individuals was
lower than expected. Potential explanations for this are
poor specificity of the anti-HCV antibody assay, poor sensi-
tivity of the HCV-RNA assay, or a true biologically higher
HCV-RNA spontaneous clearance rate in the Brazilian
setting. In our study, high sensitivity (poor specificity) of
anti-HCV was identified because of the cutoff point recom-
mended by the manufacturer; this may have increased false
positive rates. In this regard, the ROC curve showed that a
cutoff point of OD =4.0 yielded higher specificity on the
detection of viremia. The assay used (AMPLICOR™ Roche
Version 2.0) for HCV-RNA testing detects 60 International
Units per ml. A concern on the detection of hepatitis C
virus RNA in a large population survey is the specimen
handling and storage. Nevertheless, we have followed the
laboratory procedures and storage recommendations and
all tests were performed in a reference laboratory where
quality control was assured. In addition, data analysis
showed that the frequency of viremia found was consistent
across macro-regions. In general, about 25% of infected
HCV individuals have spontaneous viral clearance. A
systematic review of longitudinal studies on spontaneous
viral clearance showed that clearance was more frequent in
females and in acute clinical hepatitis C infection [37].
Furthermore, a genome-wide association study showed
that individuals with favorable IL28B genotypes are more
likely to clear HCV infection than are those with unfavor-
able alleles, which could have implications in viral clear-
ance ability among different ethnic groups [38]. In the
South of Brazil, IL28B polymorphism was associated with
spontaneous clearance of hepatitis C infection among
co-infected HCV and HIV/AIDS patients [39].
Although this survey covered a large geographical area
and enrolled a large population sample in all State Capitals
and Federal District, there was low refusal rate in all
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macro-regions, which was slightly higher in the wealthier
regions: South and Southeast. This indicates the feasibility
of nationwide-studies.
In this survey, subtypes 1a, 1b, 2b and 3a were detected
in the general Brazilian population within the macro-
regions. Overall, genotype 1 was predominant, as reported
in the literature, which suggests that genotype 1a and 1b
are the most frequent HCV genotypes worldwide,
accounting for 60% of the infections [2]. The geographical
distribution of hepatitis C virus genotypes in Brazil among
a large sample of chronic hepatitis C patients from all
regions has also shown a predominance of genotype 1 fol-
lowed by genotype 3 [19], in accordance with our findings.
Among injecting drug-users, the circulating subtypes were
1 and 3 in the studies conducted between 1994–1997 and
1999–2001 in Rio de Janeiro [40]. Our study was not
designed to identify the diversity of HCV genotypes
among the regions. We are aware that not all anti-HCV
positive individuals were tested for HCV-RNA, which may
limit the extrapolation of these results.
Conclusions
The present survey measured the hepatitis C infection
prevalence among the general population for the country
and macro-regions, and classifies Brazil as a low-
endemicity area. Nevertheless, the large estimated abso-
lute numbers of infected individuals indicate the burden
of the disease in the near future. This implies costs for
the health-care system and society as a whole, as pointed
out in other studies [41,42]. This issue needs to be
addressed by studies that evaluate the economic impact
of HCV infection. The known risk factors explain less
than 50% of the infected cases, limiting the prevention
strategies. Nevertheless, our findings regarding risk
behaviors associated with HCV infection showed that
there is still room for improving strategies for reducing
transmission among drug users. Another recommenda-
tion would be to study the extent to which nosocomial
transmission is occurring in our setting. Finally, there is
a need for targeting individuals living in poverty, in view
of the evidence found of an association between infec-
tion and social deprivation.
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